Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

July 17, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

DeliriumLocally Advanced Malignant NeoplasmMetastatic Malignant NeoplasmRecurrent Malignant Neoplasm

Interventions

DRUG

Haloperidol

Given IV

DRUG

Lorazepam

Given IV

OTHER

Placebo

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

Hosptial de Cancer de Barretos, Barretos

Virginia Commonwealth University/Massey Cancer Center, Richmond

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER